Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

China flag China · Delayed Price · Currency is CNY
30.79
-0.11 (-0.36%)
At close: Mar 9, 2026
35.34%
Market Cap 14.09B
Revenue (ttm) 1.47B
Net Income (ttm) 74.75M
Shares Out 455.90M
EPS (ttm) 0.17
PE Ratio 185.23
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,166,832
Average Volume 11,528,434
Open 30.75
Previous Close 30.90
Day's Range 30.39 - 31.25
52-Week Range 18.90 - 31.25
Beta 0.44
RSI 74.93
Earnings Date Apr 25, 2026

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 2,014
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600645
Full Company Profile

Financial Performance

In 2024, SHA:600645's revenue was 1.59 billion, a decrease of -0.27% compared to the previous year's 1.59 billion. Earnings were 100.35 million, a decrease of -5.73%.

Financial Statements

News

There is no news available yet.